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Chemotherapy-induced nausea and vomiting is ranked among the worst side effects of chemotherapy. NEPA is an
oral fixed-dose combination antiemetic under development, consisting of netupitant 300 mg, a highly selective NK1
receptor antagonist (RA), and palonosetron 0.5 mg, a pharmacologically and clinically distinct 5-HT3 RA. Although
palonosetron is not associated with relevant ECG effects, this study evaluated cardiovascular safety of netupitant
in combination with palonosetron, as well as its tolerability.
This randomised, placebo- and positively controlled study in 197 subjects included 4 treatment groups: placebo,
200 mg netupitant + 0.5 mg palonosetron (NEPA200/0.5), 600 mg netupitant + 1.5 mg palonosetron (NEPA600/1.5,
a supratherapeutic dose), and 400 mg moxifloxacin. Assessments included a 24-h baseline ECG recording, followed
by a single dose of treatment and ECG measurements for 2 days.
Mean placebo-corrected time-averaged changes from baseline were similar in NEPA200/0.5 and NEPA600/1.5 groups
primarily for individually heart rate-corrected QT interval (QTcI: +4.7 and +3.6 ms, respectively) and for heart
rate (HR: –3.3 bpm and –3.0 bpm), PR interval (–0.4 ms and 0.2 ms), and QRS interval (1 ms and 0.5 ms). The
time-matched analysis showed no upper confidence interval >10 ms, with no suggestion of a QTc effect by
pharmacokinetic-pharmacodynamic modeling for parent/metabolites. Moxifloxacin showed the expected
placebo-corrected change from baseline (+8.4 ms time average) and the expected profile to establish assay
sensitivity. No new morphologic changes of clinical relevance were observed. Treatment-related adverse events
were comparable among groups.
This study showed that NEPA treatments produced no significant effects on QTcI, HR, PR interval, QRS interval,
and cardiac morphology relative to placebo, even at supratherapeutic doses.
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Chemotherapy-induced nausea and vomiting (CINV)
is a common and distressing consequence of cytotoxic
chemotherapy. Acute CINV is described as CINV oc-
curring in the first 24 hours after administration of
chemotherapy, whereas delayed CINV begins 25 hours
or more after chemotherapy initiation, and can last
up to several days after chemotherapy is completed* Correspondence: tulla.spinelli@helsinn.com
1Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano/Pazzallo,
Switzerland
Full list of author information is available at the end of the article
© 2014 Spinelli et al.; licensee Springer. This is
Attribution License (http://creativecommons.or
in any medium, provided the original work is p(Bloechl-Daum et al. 2006; Hesketh et al. 2003). CINV
impacts patients’ quality of life and is a major reason for
noncompletion or delay of the chemotherapy programme
(Bloechl-Daum et al. 2006; Aapro et al. 2012; Cohen et al.
2007).
There are 2 major pathways known to be involved in
CINV. The neurotransmitter serotonin (5-hydroxytryp-
tamine or 5-HT) has been shown to be an important
mediator of the acute phase, while the role of substance P
is mainly related to the delayed phase of CINV (Hesketh
et al. 2003; Rojas and Slusher 2012; Feyer and Jordan 2011;
Rubenstein et al. 2006). Preclinical studies demonstratedan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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circulation of both serotonin and substance P. The 5-HT3
receptor antagonists (RAs) are thought to inhibit the
serotonin emetic pathway peripherally, while the neuro-
kinin 1 (NK1) RAs are thought to act on the substance
P-mediated signaling at the level of the central nervous
system (Hesketh et al. 2003; Rojas and Slusher 2012;
Feyer and Jordan 2011; Rubenstein et al. 2006).
International antiemetic guidelines recommend admin-
istering a 5-HT3 RA with an NK1 RA and a corticosteroid
as part of the antiemetic regimen to prevent nausea and
vomiting in patients who are at high risk to develop it
(Basch et al. 2011; Gralla et al. 2013; Roila et al. 2010;
National Comprehensive Cancer Network 2013). Never-
theless, CINV is still underestimated, particularly in the
delayed phase and with regard to nausea (Bloechl-Daum
et al. 2006; Cohen et al. 2007; Salsman et al. 2012; Roscoe
et al. 2004). This represents an area of need that should be
addressed by new and safe antiemetics.
NEPA is a new antiemetic under development that
targets a dual antiemetic pathway with a single oral fixed-
dose combination of netupitant 300 mg and palonosetron
0.5 mg to be administered prior to emetogenic che-
motherapy. The phase II and III pivotal clinical studies
demonstrating both the safety and high efficacy of this
convenient single-day antiemetic have recently been pub-
lished (Hesketh et al. 2014; Aapro et al. 2014; Gralla et al.
2014). Netupitant (2-(3,5-Bis-trifluoromethyl-phenyl)-N-
methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridine-
3-yl]-isobutyramide) is a new and selective NK1 RA
showing a high receptor occupancy level at time to
maximum plasma concentration (tmax; more than 90%)
and a long-lasting (up to 96 hours postdose) blockade
of NK1 receptors in the human brain (Spinelli et al.
2014). Chronic administration of different daily doses
of netupitant (50 mg, 100 mg, and 200 mg) for 8 weeks
raised no safety issues in patients with an overactive
bladder (Haab et al. 2014). Palonosetron ((3aS)-2-[(S)-1-
Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H
benz[de]isoquinoline hydrochloride) is a 5-HT3 RA with
a longer half-life and higher binding affinity that differs
from traditional setrons both from a pharmacologic
and clinical point of view (Reddy et al. 2006). In vitro
and in vivo studies demonstrated that palonosetron
uniquely: 1) exhibits allosteric binding to the 5-HT3
receptor, with positive cooperativity and persistent
inhibition of receptor function; 2) triggers 5-HT3
receptor internalisation; and 3) inhibits substance P-
mediated response through inhibition of the 5-HT3 and
NK1 receptor cross-talk (Rojas and Slusher 2012). Several
studies have shown that palonosetron, as a single agent or
in combination with a corticosteroid, has a high tole-
rability profile and achieves superior efficacy in pre-
venting CINV compared with the other 5-HT3 RAs(Aapro et al. 2006; Eisenberg et al. 2003; Gralla et al. 2003;
Saito et al. 2009).
Preclinical data demonstrated that NEPA synergistically
enhanced inhibition of the substance P response com-
pared to either palonosetron or netupitant alone (Stathis
et al. 2012). These data suggest that the NEPA combin-
ation represents an effective and convenient approach to
prevent acute and delayed CINV with a single oral dose.
Cardiovascular disease represents one of the most
common comorbidities in the growing population of
cancer patients aged more than 65 years (Aapro et al.
2005). Cardiopathy can be preexisting or a consequence
of the malignancy, and ECG changes can be an adverse
event (AE) resulting from chemotherapy treatment. Sev-
eral antineoplastic agents (especially anthracyclines) and
some platinum compounds are associated with ECG
alterations, including prolongation of the QT interval,
development of ventricular late potentials, and various
arrhythmias. It has been shown that the interaction of
anthracyclines with the monoclonal antibody trastuzu-
mab, which is quite common in breast cancer patients,
can potentiate cardiotoxic effects (Bagnes et al. 2010).
Cyclophosphamide treatment has been associated with
7% to 28% incidence of heart failure, while cisplatin has
been associated with 8.5% of venous thromboembolism
incidence (Vo and Nelson 2012). The use of 5-fluorouracil
has been reported to be associated with ECG changes (eg,
ST segment deviation and corrected QT interval [QTc]
prolongation in nearly 68% of patients) and cardiotoxicity
(eg, angina, supraventricular tachycardia, and myocardial
infarction with an incidence of 1%–18%) (Sorrentino et al.
2012). Cardiotoxicity has also been reported after admi-
nistration of taxanes (eg, brady- and tachyarrhythmia and
other cardiac disturbances) (Bagnes et al. 2010; Yeh and
Bickford 2009). The incidence of bradycardia associated
with paclitaxel treatment ranges from <0.1% to 31% and
the incidence of heart failure associated with docetaxel
treatment ranges from <2.3% to 8% (Yeh and Bickford
2009). Both paclitaxel (<1%–5% incidence) and docetaxel
(1.7% incidence) have been associated with myocardial
ischaemia (Yeh and Bickford 2009).
Not only chemotherapeutic agents, but also newer
targeted agents have been shown to lead to cardio-
toxicity (Bagnes et al. 2010; Hedhli and Russell 2011).
Multikinase-targeted drugs (eg, sorafenib, sunitinib, ima-
tinib, and dasatinib) are associated with various cardiac
effects, such as hypertension, congestive heart failure,
and QTc prolongation (Bagnes et al. 2010; Hedhli and
Russell 2011). The use of histone deacetylase inhibi-
tors has also been associated with QTc prolongation
(Bagnes et al. 2010; Hedhli and Russell 2011). Adminis-
tration of anti-vascular endothelial growth factor agents
(eg, bevacizumab and aflibercept) can lead to hyper-
tension, arrhythmia, and thromboembolic effects, such as
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The current double-blind, randomised, parallel-group
study evaluated whether the combined administration of
different doses of netupitant + palonosetron prolongs the
individually heart rate-corrected QT interval (QTcI)
more than placebo. Safety and tolerability of the combi-
nation therapy, as well as pharmacokinetic (PK) data,
were evaluated.
Methods
Study design and treatment
This was a phase I, randomised, double-blind (except
for the use of moxifloxacin), double-dummy, parallel-
group, placebo- and open-label positively controlled
study (EudraCT: 2007-004365-17). The study was approved
by appropriate ethics committees and was conducted in
accordance with the Declaration of Helsinki, the German
Drug Law, and the German Good Clinical Practice decree.
All subjects gave written informed consent to participate
in the trial. The primary objective of this study was to
assess whether the combined administration of different
doses of netupitant + palonosetron prolongs QTcI more
than placebo. Secondary objectives were to evaluate the
safety and tolerability of NEPA combinations and assess
the PK of netupitant, palonosetron, and their metabolites.
The trial design followed the provisions of ICH Guide-
line E14 for a “thorough QT/QTc study” (US Depart-
ment of Health and Human Services 2005). The study
consisted of an ambulant screening phase (days –21 to –3),
a pre-check period (day –2 and –1), a treatment period
(days 1–3), and an ambulant final check 14 to 21 days
after discharge from the study center on day 3. Subjects
were hospitalised from the evening of day –2 until day 3.
Subjects were randomly assigned to one of the following
single-dose treatment groups: placebo, 200 mg netupi-
tant + 0.50 mg palonosetron (NEPA200/0.5), 600 mg
netupitant + 1.50 mg palonosetron (NEPA600/1.5), and
400 mg moxifloxacin (Avelox®, Bayer Healthcare; posi-
tive control). A 24-hour baseline ECG was followed by a
single dose of treatment on day 1, after which subjects
had ECG and PK measurements up to 48 hours postdose.
Subjects
Two hundred healthy subjects (at least 92 of each gender)
aged 18 to 45 years were included if they had a body mass
index of 19 to <29 kg/m2, were nonsmokers (or refrained
from smoking or taking other nicotine-containing pro-
ducts for 3 months prior to dosing), and had normal blood
pressure (55–89/95–149 mmHg) and pulse rate (45–95
beats/minute). Subjects with any of the following were
excluded: current use of oral contraceptives or hormones
within 3 months prior to dosing; pregnant or breast-
feeding; use of prescribed or over-the-counter medicationwithin 14 days of dosing; any active physical disease (acute
or chronic); gastrointestinal complaints within 7 days of
dosing; febrile or infectious illness within 7 days of dosing;
any cardiovascular condition; any abnormal ECG interval
or changes in ECG that might interfere with measurement
of QT interval; relevant drug hypersensitivity (specifically
against moxifloxacin); known contraindication to NK1
RAs, 5-HT3 RAs, or fluoroquinolones; positive test for
hepatitis B virus, hemoglobin C, or human immunodefi-
ciency virus; or any other reason deemed unsuitable in the
opinion of the investigator.
Pharmacodynamics
ECGs were obtained using a continuous 12-lead digital
Holter recorder (Mortara H-12; Milwaukee, WI) on day –1
(baseline) and on days 1 and 2. ECGs to be used in the
analysis were selected at the following predetermined time
points: day –1 at –23, –22, –20, –19, –18, –17, –16, –14,
–12, –10, –8, –6, and –0.5 hours; days 1 and 2 at 1, 2, 4, 5,
6, 7, 8, 10, 12, 14, 16, 18, 23.5, 30, 36, 42, and 47.5 hours.
Four ECGs were obtained at each time point. Three kinds
of QTc were calculated. The primary ECG endpoint was
QTcI, calculated as QTcI =QT/(RR)slope, where the slope
was determined for each subject by linear regression ana-
lysis on the baseline ECGs. Secondary ECG variables inclu-
ded frequency correction performed using the Fridericia
formula (QTcF) and frequency correction performed using
Bazett formula (QTcB). Additionally, the following parame-
ters were evaluated: uncorrected QT interval, heart rate
(HR), PR interval, QRS interval, and change in ECG mor-
phologic patterns.
Pharmacokinetics
The area under the plasma concentration-time curve
data from administration until the last sampling point
(AUC0-t), maximum plasma concentration (Cmax), and
tmax were determined for netupitant (and its metabolites
M1, M2, and M3) and palonosetron (and its metabolites
M4 and M9), if data permitted. AUC0-t was calculated
by the linear trapezoidal formula, Cmax was defined as
the highest observed plasma concentration of the mea-
sured concentration-time profile, and tmax was set as the
time after administration at which Cmax occurred.
A simultaneous, validated, internally standardised
liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method with electrospray ionisation in
the positive mode was used for the analysis of netupi-
tant and its metabolites M1, M2, and M3 and palono-
setron and its metabolites M4 and M9. The analytics
methods used for determination of netupitant and
palonosetron and their metabolites are validated and
approved by the US Food and Drug Administration
and European Medicines Agency guidelines and were
performed accordingly.
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Safety and tolerability parameters included physical
examination, vital signs, body temperature, body weight,
ECG recording, and laboratory examinations (clinical
chemistry, haematology, urinalysis, serology, drug screen
and alcohol breath test, and pregnancy test). AEs were
ascertained and rated by the investigators. Overall to-
lerability was assessed by the investigator at the end
of the study.
Statistics methods
Biometric and PK evaluation were carried out using
SAS® (Version 9.1). Descriptive statistics were used to
summarise demographic data and ECG variables at each
time point. For the QTc analysis, 2-sided 90% confidence
intervals (CIs) based on the intersection–union test were
calculated for each matched time (time-matched ana-
lysis). If the upper limit of the 2-sided 90% CI for the
study treatment versus placebo did not exceed 10 milli-
seconds (ms) at any time point, it was concluded that
this dose did not prolong the QTc interval to a clinically
significant degree. To establish assay sensitivity, at least
1 time point with a mean difference of moxifloxacin and
placebo >5 ms had to be observed.
In addition to the time-matched analysis, the time-
averaged analysis was calculated. For each subject and
for the ECG parameters QTc (I, B, F), HR, PR, QRS, and
QT, the mean of all baseline ECGs was calculated as the
time-averaged baseline value, and the mean of all post-
dose ECGs was calculated as the time-averaged postdose
value. The time-averaged change from baseline was
calculated from both values. The placebo-corrected
time-averaged change from baseline was calculated by
subtracting the mean placebo baseline-corrected values
from the mean time-averaged change from baseline of the
other treatment groups.
The PK/pharmacodynamics (PD) analysis explored the
relationship between the placebo-adjusted QTcI change
from baseline and plasma concentrations of netupitant
and palonosetron. A linear mixed-effects modeling ap-
proach was adopted in which this PK/PD relationship
was a fixed effect with subject included as a random
effect (ΔΔQTcI = α + β ∗ [plasma concentration] + γ ∗
[subject effect]). This model was used to estimate the
population slope and the standard error (SE) of the
slope. A linear relationship was declared if the p-value of
the slope was <0.05. The mean maximum effect (Cmax ∗ β)
and the upper 1-sided 95% CI (Cmax ∗ β + [1.65 ∗ SE β ∗
Cmax]) were calculated.
A sample size of 50 subjects per group was expected
to provide at least 80% power to show for the compari-
son of netupitant/palonosetron to placebo that the upper
limit of the 90% CI falls below 10 ms. The sample size
was calculated based on an assumed standard deviationof 11 ms. The true difference between time-matched
changes from baseline QTcI of netupitant/palonosetron
and placebo groups was selected as 3 ms.
Results
Disposition and baseline characteristics
Two hundred subjects (106 males and 94 females) were
enrolled in the study. Five women withdrew consent and
discontinued the study. Three of them withdrew their con-
sent before treatment administration and were therefore
not included in any analysis. One subject in the NEPA200/
0.5 group did not show netupitant plasma levels and was
therefore excluded from the PD analyses. One hundred
ninety-five subjects completed the study. The baseline
characteristics of the study population were comparable
between treatment groups and are shown in Table 1.
Pharmacodynamics
One hundred ninety-six subjects were included in the
PD analyses. Because heart rate inversely affects QT
duration, the assessment of cardiac repolarisation was
based on QTcI. The QTcI mean time-averaged placebo-
corrected change from baseline for NEPA200/0.5 and
NEPA600/1.5 was +4.7 and +3.6 ms, respectively (Table 2).
For QTcB, values were –0.9 and –0.5 ms for NEPA200/0.5
and NEPA600/1.5 groups, respectively. For the time-averaged
analysis, the mean placebo-corrected change from
baseline for heart rate was similar for the NEPA200/0.5
and NEPA600/1.5 groups (–3.3 and –3.0 bpm, respectively;
Table 2). Mean placebo-corrected change from baseline
for PR and QRS durations was similar for the NEPA200/0.5
(PR: –0.4 ms; QRS: 1.0 ms) and NEPA600/1.5 (PR: 0.2 ms;
QRS: 0.5 ms) groups, and was not considered clinically
relevant (Table 2).
These data showed no signs for an effect of different
doses of netupitant + palonosetron on QTc (Table 2). In
the moxifloxacin-treated group, the placebo-corrected
mean change from baseline for QTcI and QTcB values
was +8.4 and +8.5 ms, respectively (expected 5–10 ms),
indicating assay sensitivity was reached (Table 2). In the
placebo group the QTcI and QTcB mean changes from
baseline were –2.1 and –3.0 ms, respectively, showing
that background QTc was controlled (Table 2).
A time-matched analysis was conducted as recom-
mended by ICH E14 with placebo- and baseline-corrected
QTcI data for NEPA and moxifloxacin dose groups. The
analysis for QTcI revealed that the moxifloxacin group
met the assay sensitivity criteria with 12 time points above
a mean of 5 ms (Table 3, Figure 1a). Results showed that
the NEPA groups did not exceed the upper CI of 10 ms at
any of the time points (Table 3, Figure 1a). Therefore,
the combination of different doses of netupitant and
palonosetron did not prolong the QTc interval to a
clinically significant degree.
Table 1 Baseline characteristics
Placebo (N = 50) NEPA200/0.5 (N = 49) NEPA600/1.5 (N = 49) Moxifloxacin (N = 49)
Age, years
Mean (SD) 34.7 (7.12) 33.6 (6.86) 32.8 (8.36) 34.7 (7.98)
Min–max 19–45 21–44 19–45 19–45
Gender, n (%)
Male 26 (52) 27 (55) 27 (55) 26 (53)
Female 24 (48) 22 (45) 22 (45) 23 (47)
BMI, kg/m2
Mean (SD) 24.45 (2.486) 24.27 (2.608) 24.51 (2.516) 24.89 (2.674)
Min–max 19.0–28.9 19.2–28.5 19.4–28.9 19.4–29.0
BMI, body mass index; SD, standard deviation.
NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
Percentages are based on N.
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logic changes were not considered clinically significant
in any dose group and there were no imbalances in the
NEPA200/0.5 and NEPA600/1.5 groups.
Pharmacokinetics
PK parameters were assessed for netupitant and its
metabolites M1, M2, and M3 and palonosetron and
its metabolites M9 and M4.
A dose-proportional increase of the geometric mean
AUC0-t was observed for netupitant (4079 h ∗ μg/L at
200 mg to 12213 h ∗ μg/L at 600 mg) and palonosetron
(22641 h ∗ ng/L at 0.5 mg to 67918 h ∗ ng/L at 1.5 mg).
Similarly, Cmax increased with dose for both netupitant
(219 μg/L to 648 μg/L) and palonosetron (822 ng/L to
2588 ng/L; Table 4). The intersubject PK variability was
higher for netupitant than for palonosetron. TheTable 2 Time-averaged analysis: mean changes from baseline
Endpoint Parameter










Primary QTcI, ms –2.1 2.6 4.7
(Min;max) (−8.3; 4.8) (−5.8; 30.6)
Secondary HR, bpm –0.7 –4.0 –3.3
PR, ms 1.1 0.7 –0.4
QRS, ms –0.3 0.7 1.0
QT, ms –0.4 9.3 9.7
QTcF, ms –2.1 0.5 2.6
QTcB, ms –3.0 –3.9 –0.9
bpm, beats per minute; min, minimum; max, maximum; HR, heart rate; ms, milliseco
heart rate-corrected QT interval.
NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50
NEPA 600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).intersubject variability of netupitant for AUC0-t and Cmax
was 42% and 48% at 200 mg, and 47% and 56% at
600 mg. For palonosetron, the intersubject variability for
AUC0-t and Cmax varied from 20% to 29%. The pharmaco-
kinetics of netupitant and palonosetron, including their
metabolites, confirm that the ECG time points were
adequately chosen, since the Cmax of all analytes lie within
the ECG measurement time points.
Pharmacodynamics/pharmacokinetics relationship
The relationship between placebo- and baseline-corrected
QTcI duration and plasma concentration from paired sam-
ples taken in both dose groups for netupitant (Figure 1b)
and palonosetron (Figure 1c) was evaluated. There were no
indications that exposure to netupitant or palonosetron
(parent or M1, M2, or M3 metabolites for netupitant; M9













1.5 3.6 6.3 8.4
(−7.3; 14.3) (−2.6; 15.3)
–3.7 –3.0 –0.4 0.3
1.3 0.2 –0.2 –1.3
0.2 0.5 0.0 0.3
8.6 9.0 6.9 7.3
0.5 2.6 6.0 8.1
–3.5 –0.5 5.5 8.5
nds; QTcB, Bazett correction; QTcF, Fridericia correction; QTcI, individually
mg).
Table 3 Time-matched analysis: placebo and baseline corrected QTcI data for NEPA and moxifloxacin dose groups
Time, h NEPA200/0.5 NEPA600/1.5 Moxifloxacin
Estimate1 Upper bound2 Estimate1 Upper bound2 Estimate1 Upper bound2
1 3.2 5.2 3.5 5.3 12.2 15.1
2 3.8 5.9 1.0 2.8 12.7 15.6
4 5.5 7.6 1.7 3.5 13.7 16.6
5 4.8 6.9 2.5 4.3 12.2 15.1
6 3.5 5.6 4.3 6.1 9.7 12.6
7 4.5 6.5 4.1 5.9 10.5 13.4
8 5.3 7.4 4.3 6.1 9.6 12.6
10 6.1 8.1 5.2 7.0 10.8 13.7
12 5.7 7.8 3.6 5.4 9.2 12.1
14 6.7 8.7 4.9 6.7 7.5 10.4
16 5.5 7.6 7.0 8.8 8.0 10.9
18 6.0 8.1 5.3 7.1 7.1 10.0
23.5 1.7 3.7 3.3 5.1 4.7 7.6
30 4.9 7.0 4.4 6.2 5.2 8.1
36 3.9 6.0 3.2 5.0 3.8 6.7
42 4.3 6.4 0.8 2.6 3.0 5.9
47.5 1.8 3.8 0.6 2.4 2.3 5.3
Time average 4.6 5.7 3.4 4.5 8.4 9.5
ANOVA, analysis of variance; QTcI, individually heart rate-corrected QT interval.
NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
1Mixed-model ANOVA is fit for placebo-corrected change from baseline and includes terms for treatment, gender, time, and a time-by-treatment interaction.
2Upper bound, upper 1-sided 95% ANOVA model-based confidence limit.
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Safety and tolerability
During the study, a total of 60 AEs were reported by 49
subjects. AEs were reported for 12 (24.0%) subjects in
the placebo, 10 (20.4%) in the NEPA200/0.5, 17 (34.7%) in
the NEPA600/1.5, and 10 (20.4%) in the moxifloxacin groups.
Possibly or probably treatment-related AEs (TRAEs) were
reported for 9 (18.0%) placebo subjects and 8 (16.3%),
10 (20.4%), and 8 (16.3%) subjects in the NEPA200/0.5,
NEPA600/1.5, and moxifloxacin groups, respectively
(Table 5). The incidence of TRAEs in the NEPA200/0.5
group was comparable to that of the placebo and moxi-
floxacin groups, although the frequency of TRAEs was
slightly higher with NEPA600/1.5. With NEPA200/0.5 treat-
ment, most commonly reported TRAEs were consti-
pation (3 subjects), followed by upper abdominal pain (2
subjects), and headache (2 subjects). In the NEPA600/1.5
group, headache (5 subjects) was most commonly repor-
ted, followed by constipation (2 subjects). Subjects treated
with moxifloxacin reported mainly dizziness (3 subjects)
and headache (2 subjects).
No deaths occurred during the study. One subject had
a serious AE (injury) caused by a staircase accident andrecovered by the end of the study. The investigator
assessed the event as unlikely related to study drug. No
clinically significant laboratory changes were observed
and there were no AEs associated with laboratory changes.
No abnormalities were detected in vital signs or ECG. The
overall tolerability was assessed as good in 193 subjects
and as satisfactory in 4 subjects.
Discussion
NEPA is an oral fixed-dose combination of netupitant
300 mg and palonosetron 0.5 mg targeting dual anti-
emetic pathways mediated by serotonin and substance
P with a single administration on the day of chemo-
therapy. Since the incidence of cancer patients with
cardiovascular-related diseases is growing, especially in
the elderly population, the cardiac safety profile of
drugs used for supportive care should be investigated.
As recommended by international antiemetic guidelines,
especially in patients undergoing highly emetogenic
chemotherapy, an NK1 RA, a 5-HT3 RA, and a cortico-
steroid are commonly coadministered to prevent CINV
(Basch et al. 2011; Gralla et al. 2013; Roila et al. 2010;
National Comprehensive Cancer Network 2013). Aprepi-
tant and its prodrug fosaprepitant are the only NK1 RAs
currently available and used in clinical practice. A recent
dQTcl = 3.6 + (0.0013)*(Netupitant Plasma Concentration)
Predicted dQTcI = 4.3
Cmax = 532.4
Netupitant Plasma Concentration (µg/L)
Estimate of the slope of the relationship between plasma concentration
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Predicted dQTcI = 4.2
Cmax = 1746.8
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Figure 1 (See legend on next page.)
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Figure 1 Placebo- and baseline-corrected change in QTcI. (a) Placebo- and baseline-corrected change in QTcI for each time point in each
treatment group. (b) Pharmacokinetic/pharmacodynamics relationship: placebo- and baseline-corrected change in QTcI versus netupitant plasma
concentrations and (c) versus palonosetron plasma concentrations.
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fosaprepitant reported no clinically relevant effect on
QTc interval at any time after infusion (including apre-
pitant tmax) (Marbury et al. 2009; Emend (aprepitant)
Prescribing Information 2006). The cardiovascular safety of
another NK1 RA whose development was recently inter-
rupted, casopitant, was evaluated and similarly showed no
evidence of QTc prolongation after a 3-day oral regimen
(Johnson et al. 2010).
Although 5-HT3 RAs such as dolasetron, ondansetron,
and granisetron are perceived as safe by the medical
community, cardiovascular issues have been reported.
Ondansetron 4 mg has been associated with a statisti-
cally significant increased prolongation of QTc at various
time points following administration in healthy subjects
or surgical patients without additional risk factors for
QTc prolongation (Charbit et al. 2005, 2008; Benedict
et al. 1996; Zofran (ondansetron hydrochloride) Prescri-
bing Information 2011). Although an adequate QT assess-
ment was not conducted, QT prolongation has been
associated with the use of granisetron, as shown in a studyTable 4 Descriptive statistics of PK parameters for netupitant




















AUC0-t, area under the plasma concentration-time curve data from administration unti
PK, pharmacokinetic; SD, standard deviation; tmax, time to Cmax.
NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50
NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).by Alidoosti et al. reporting prolongation of PR and QTc,
and a decrease in HR in cancer patients (Alidoosti et al.
2009; Kytril (granisetron hydrochloride) Prescribing Infor-
mation 2011). Dolasetron treatment resulted in dose-
related increases in HR, PR intervals, and QRS intervals
and a statistically significant increase in QTc interval
(Benedict et al. 1996). Based on clinical evidence, dolase-
tron and the highest dose of ondansetron (32 mg) are no
longer indicated for CINV prevention due to cardiovascu-
lar safety concerns. Contrary to these findings, recent
studies, including a formal ICH E14 thorough QT trial,
have reported that palonosetron does not prolong the QT
interval and does not cause any significant acute change
in repolarisation (QTc, corrected QT dispersion [QTcd])
or transmural dispersion indices (TpTe, TpTed, and
TpTe/QT) (Dogan et al. 2012; Gonullu et al. 2012;
Morganroth et al. 2007). The thorough QT/QTc (ICH
E14) study in healthy subjects also demonstrated that
palonosetron has no effect on the QT interval (QT/QTc)
over the 0.25- to 2.25-mg range of exposure (Morganroth
et al. 2007; Aloxi (palonosetron hydrochloride) Prescribingand palonosetron
ax (μg/L) Geo. Mean (Geo. SD) tmax (h) Geo. Mean (Geo. SD)
218.7 (1.833) 5.218 (1.589)
23.55 (1.594) 14.54 (1.668)
96.94 (1.842) 3.580 (1.342)
46.73 (1.559) 10.70 (1.490)
647.7 (2.205) 6.104 (1.474)
53.71 (1.763) 17.82 (1.948)
227.8 (2.024) 4.131 (1.208)
101.5 (1.822) 11.51 (1.555)
ax (ng/L) Geo. Mean (Geo. SD) tmax (h) Geo. Mean (Geo. SD)
821.6 (1.277) 5.464 (1.437)
72.72 (1.379) 3.675 (1.764)
105.0 (1.383) 1.746 (1.348)
2588 (1.239) 4.229 (1.693)
231.0 (1.330) 3.388 (1.734)
348.9 (1.313) 1.781 (1.535)
l the last sampling point; Cmax, maximum plasma concentration; Geo., geometric;
mg).
Table 5 Possibly or probably drug-related adverse events
Adverse event Placebo NEPA200/0.5 NEPA600/1.5 Moxifloxacin
Number of subjects (%) (N = 50) (N = 49) (N = 49) (N = 49)
Cardiac disorders
Palpitations 0 0 1 (2.0) 0
Gastrointestinal disorders
Abdominal pain upper 0 2 (4.1) 0 0
Constipation 0 3 (6.1) 2 (4.1) 0
Dry mouth 1 (2.0) 0 0 0
Dyspepsia 1 (2.0) 0 0 0
Flatulence 1 (2.0) 0 0 0
Nausea 0 0 0 1 (2.0)
General disorders and administration-site conditions
Fatigue 0 1 (2.0) 0 1 (2.0)
Thirst 0 0 0 1 (2.0)
Musculoskeletal and connective tissue disorders
Muscle twitching 1 (2.0) 0 0 0
Pain in extremity 0 0 1 (2.0) 0
Sensation of heaviness 1 (2.0) 0 0 0
Nervous system disorders
Dizziness 1 (2.0) 0 1 (2.0) 3 (6.1)
Headache 5 (10.0) 2 (4.1) 5 (10.2) 2 (4.1)
Somnolence 0 0 1 (2.0) 0
Psychiatric disorders
Anxiety 0 0 1 (2.0) 0
Euphoric mood 0 0 1 (2.0) 0
Total 9 (18.0) 8 (16.3) 10 (20.4) 8 (16.3)
NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
Percentages are based on N.
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effects of palonosetron on heart rate or blood pressure
(Yavas et al. 2012).
This thorough ECG trial enrolled 200 healthy subjects
to assess the impact of different doses of netupitant +
palonosetron on cardiac repolarisation. The suprathera-
peutic dose of NEPA (NEPA600/1.5) was used to mimic
exposure in healthy subjects that may occur in the target
population under the worst circumstances (eg, concomi-
tant liver disease, presence of heart disease, taking more
than the prescribed clinical dose, etc.).
The present data demonstrate that different doses of
NEPA have no significant effects on QTcl, HR, PR interval
duration, QRS interval duration, or cardiac morphology
compared with placebo. The validity of this trial was
demonstrated by the fact that the moxifloxacin-positive
control group showed the expected change in QTc
duration to establish assay sensitivity. The placebo group’schange from baseline was within 3.0 ms, indicating that
spontaneous factors for QTc change are well con-
trolled. A dose-proportional increase in AUC0-t and
Cmax was observed for both netupitant and palonosetron.
Administration of different doses of NEPA was safe and
well tolerated in healthy subjects. Most commonly repor-
ted TRAEs with NEPA groups were constipation, abdo-
minal pain, and headache. Although TRAEs were slightly
more frequent with NEPA600/1.5, the dose combination
was safe with an acceptable tolerability profile.
This trial was performed in healthy subjects (18–45
years) to eliminate variables that are known to change
ECG parameters, such as concomitant drugs and diseases.
This study did not assess the cardiac safety of NEPA in
cancer patients. However, a phase III study testing NEPA
in cancer patients (without any serious cardiovascular
disease history or predisposition to cardiac conduction
abnormalities) receiving chemotherapy showed that there
Spinelli et al. SpringerPlus 2014, 3:389 Page 10 of 11
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cardiac AEs and ECGs (Hesketh et al. 2014; Aapro et al.
2014; Gralla et al. 2014). Therefore, both in cancer
patients and in healthy volunteers NEPA did not show any
increased risk in cardiac safety profile.
In conclusion, in this thorough QT trial, different
NEPA combinations showed no ECG effects, which
should predict a lack of cardiac safety concerns in clinical
practice. Treatments were well tolerated.
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